E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012601 |
E.1.2 | Term | Diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to determine the efficacy of taspoglutide versus placebo on glycemic control (as assessed by HbA1c) after 24 weeks of treatment, in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone. |
|
E.2.2 | Secondary objectives of the trial |
• Absolute/percentage change from baseline in fasting plasma glucose (FPG). • Absolute/percentage change from baseline in body weight. • Responder rates, defined as target HbA1c: ≤ 7.0%, ≤ 6.5%. • Absolute/percentage change from baseline in lipid profile: triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol and LDL/HDL ratio. • Beta cell function (indexed by fasting pro-insulin concentration, fasting proinsulin/ insulin ratio, HOMA-B). • To assess the safety and tolerability of taspoglutide. • To describe the pharmacokinetics of taspoglutide and to estimate between-patient variability using a population PK approach, exploring and quantifying the potential influence of covariates that contribute significantly to the between-patient differences in PK parameters of taspoglutide. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Roche Sample Repository Research Project in association with protocol BC20963, A multicenter, randomized, double-blind,placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled withmetformin plus pioglitazone.
Protocol BC20963RG version 1 dated May 9, 2008.
Objectives :To obtain a single blood sample from consenting patients enrolled in associated study BC20963 for pharmacogenetic and genetic research analysis. |
|
E.3 | Principal inclusion criteria |
1. Men and women, aged 18 – 75 years at screening. Women of childbearing potential, using two medically approved birth control methods (e.g. hormonal contraceptives, IUD, barrier contraception), must be willing to use the same methods of contraception during the whole course of the study. 2. Treatment with pioglitazone ≥ 30 mg/day and metformin at > 1500 mg/day, or the maximum tolerated dose or the maximum dose specified in the label, for at least 12 weeks, including at least 12 weeks on stable dose prior to screening. 3. HbA1c ≥ 7.0 and ≤ 10.0 % at screening. 4. Body mass index (BMI) > 25 (> 23 for Asians) and < 45 kg/m2 at screening. 5. Stable weight ± 5% for at least 12 weeks prior to screening. 6. Agreement to maintain prior diet and exercise habits during the full course of study. 7. Ability and willingness to give written informed consent and to comply with the requirements of the study. |
|
E.4 | Principal exclusion criteria |
1. Women who are pregnant, intending to become pregnant during the study period or currently lactating females. 2. Diagnosis or history of: • Type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes, e.g., acromegaly or Cushing’s Syndrome. • Acute metabolic diabetic complications, such as ketoacidosis or hyperosmolar coma within the past 6 months. 3. Evidence of clinically significant diabetic complications. 4. Clinically symptomatic gastrointestinal (GI) disease, including, but not limited to, inflammatory bowel disease, celiac disease, diabetic gastroparesis. 5. History of gastric bypass or antrectomy or small bowel resection. 6. History of chronic pancreatitis or idiopathic acute pancreatitis. 7. Myocardial infarction (MI), coronary artery bypass surgery, post-transplantation cardiomyopathy (PTCM) or stroke within the past 6 months. 8. Any abnormality in clinical laboratory tests or ECG, which precludes safe involvement in the study as judged by the Investigator. 9. Clinically relevant QTc prolongation (e.g. QTc > 480 ms), family history of Long QT Syndrome, or concomitant use of class I antiarrhythmic drugs (e.g. disopyramide, quinidine, procainamide, mexiletine, flecainide, propafenone). 10. Diagnosed and/or treated malignancy (except basal cell skin cancer, in situ carcinoma of the cervix or in situ prostate cancer) within the past 5 years. 11. Known hemoglobinopathy or chronic anemia. 12. Donation of one unit (500 ml) or more of blood, significant blood loss equal to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks. 13. Any concurrent medical condition/disorder that -in the opinion of the Investigator- is likely: • To interfere with the patient’s ability to complete the entire study period or to participate in all aspects of the trial; • To require, during the study, the administration of a treatment that would affect the interpretation of the efficacy and safety data. 14. Contraindications and warnings according to the country-specific label information for metformin and pioglitazone not listed in the other exclusion criteria. 15. Known hypersensitivity to pioglitazone or metformin or any of their components. 16. Treatment with any oral anti-diabetic medication (other than metformin and pioglitazone), and/or herbal/over the counter preparations that may affect glycemic control within 12 weeks prior to screening. 17. Treatment with exenatide or exendin analogues, GLP-1 or GLP-1 analogues at any time during the past. 18. Treatment with insulin (except during pregnancy) for more than one week within 6 months prior to screening. 19. Chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 4 weeks prior to screening. 20. Treatment with weight lowering agents (e.g. orlistat, sibutramine, rimonabant, phentermine) during the last 12 weeks prior to screening. 21. History of unstable hypertension (SBP > 170 mmHg and/or DBP > 105 mmHg) within the past 12 weeks prior to screening. 22. Treatment with anti-hypertensive medications which are not on a stable dose for at least 4 weeks prior to baseline. 23. Treatment with lipid lowering medications which are not on a stable dose for at least 8 weeks prior to screening. 24. Treatment with thyroid hormones which are not on a stable dose for at least 12 weeks prior to screening. 25. Use of investigational drugs within 30 days or 5 half-lives (whichever is longer) prior to screening, unless local health authority guidelines mandate longer period. 26. Any of the following laboratory abnormalities at screening: • ALT and/or AST > 3 times the upper limit of the normal range; • Serum creatinine levels ≥ 132 μmol/L (1.5 mg/dL) in males, and ≥ 123 μmol/L (1.4 mg/dL) in females; • Fasting triglycerides > 5.6 mmol/L (> 500 mg/dL); • Clinically significant TSH outside of the normal range. 27. History of active substance abuse (including alcohol) within the past 2 years. 28. Potentially unreliable patients and those judged by the Investigator to be unsuitable for the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Absolute change from baseline in HbA1c.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |